VUKANEOS PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
VUKANEOS PHARMA
Largest movements
- Receivables within one year +€19,865
up €19,865 (+61.6%), from €32,247 to €52,113
of which Other amounts receivable: +€17,578
- Cash -€794
down €794 (-99.5%), from €798 to €4
mainly Receivables within one year (-€19,865) and Deferred charges and accrued income (-€423)
- Profit (loss) carried forward +€6,722
up €6,722 (+29.8%), from -€22,594 to -€15,872
- Reserves +€5,000
up €5,000 (+33.3%), from €15,000 to €20,000
- Tax, wage and social debts +€4,431
up €4,431 (+22.1%), from €20,026 to €24,456
- Trade debts +€3,342
up €3,342 (+151%), from €2,216 to €5,557
- Gross operating margin +€4,308
up €4,308 (+32.0%), from €13,467 to €17,774
- Financial income +€2,491
new in 2022: €2,491
- Other operating charges +€2,330
up €2,330 (+207%), from €1,126 to €3,456
From the 2021 result to the 2022 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2021 and 2022 balance sheets and the 2022 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2021 | 2022 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €33,247 | €52,741 | +€19,494 | +58.6% |
| Current assets | 29/58 | €33,247 | €52,741 | +€19,494 | +58.6% |
| Amounts receivable within one year | 40/41 | €32,247 | €52,113 | +€19,865 | +61.6% |
| Trade receivables | 40 | €7,481 | €9,768 | +€2,287 | +30.6% |
| Other amounts receivable | 41 | €24,766 | €42,345 | +€17,578 | +71.0% |
| Cash at bank and in hand | 54/58 | €798 | €4 | -€794 | -99.5% |
| Deferred charges and accrued income | 490/1 | €202 | €625 | +€423 | +209% |
| Total equity and liabilities | 10/49 | €33,247 | €52,741 | +€19,494 | +58.6% |
| Equity | 10/15 | €11,006 | €22,728 | +€11,722 | +107% |
| Contributions | 10/11 | €18,600 | €18,600 | = | 0.0% |
| Contributions outside capital | 11 | €18,600 | €18,600 | = | 0.0% |
| Other | 1109/19 | €18,600 | €18,600 | = | 0.0% |
| Reserves | 13 | €15,000 | €20,000 | +€5,000 | +33.3% |
| Distributable reserves | 133 | €15,000 | €20,000 | +€5,000 | +33.3% |
| Profit (loss) carried forward | 14 | -€22,594 | -€15,872 | +€6,722 | +29.8% |
| Amounts payable | 17/49 | €22,241 | €30,014 | +€7,772 | +34.9% |
| Amounts payable within one year | 42/48 | €22,241 | €30,014 | +€7,772 | +34.9% |
| Trade debts | 44 | €2,216 | €5,557 | +€3,342 | +151% |
| Suppliers | 440/4 | €2,216 | €5,557 | +€3,342 | +151% |
| Taxes, remuneration and social security | 45 | €20,026 | €24,456 | +€4,431 | +22.1% |
| Taxes | 450/3 | €20,026 | €24,456 | +€4,431 | +22.1% |
| Other operating charges | 640/8 | €1,126 | €3,456 | +€2,330 | +207% |
| Gross operating margin | 9900 | €13,467 | €17,774 | +€4,308 | +32.0% |
| Operating profit (loss) | 9901 | €12,340 | €14,318 | +€1,978 | +16.0% |
| Financial income | 75/76B | - | €2,491 | +€2,491 | |
| Recurring financial income | 75 | - | €2,491 | +€2,491 | |
| Financial charges | 65/66B | €469 | €616 | +€146 | +31.2% |
| Recurring financial charges | 65 | €469 | €616 | +€146 | +31.2% |
| Profit (loss) for the period before taxes | 9903 | €11,871 | €16,193 | +€4,322 | +36.4% |
| Income taxes | 67/77 | €4,341 | €4,471 | +€130 | +3.0% |
| Profit (loss) for the period | 9904 | €7,530 | €11,722 | +€4,192 | +55.7% |
| Profit (loss) for the period to be appropriated | 9905 | €7,530 | €11,722 | +€4,192 | +55.7% |
Source: filed annual accounts (NBB), financial years ended 31 December 2021 and 31 December 2022. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 17 October 2026 via checked.be.